Serum biomarkers of cardiovascular complications in covid-19

R. M. Gumerov; D. F. Gareeva; P. A. Davtyan; R. F. Rakhimova; T. I. Musin; Sh Z. Zagidullin; A. E. Pushkareva; M. R. Plotnikova; V. Sh Ishmetov; V. N. Pavlov; L. J. Motloch; N. Sh Zagidullin

doi:10.15829/1560-4071-2021-4456

Serum biomarkers of cardiovascular complications in covid-19

R. M. Gumerov, D. F. Gareeva, P. A. Davtyan, R. F. Rakhimova, T. I. Musin, Sh Z. Zagidullin, A. E. Pushkareva, M. R. Plotnikova, V. Sh Ishmetov, V. N. Pavlov, L. J. Motloch, N. Sh Zagidullin

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The coronavirus disease 2019 (COVID-19) affects not only the respiratory system, but also the cardiovascular system in 20-28% of cases, causing endothelial dysfunction, vasculitis, hyper-and hypocoagulation, myocarditis, endothelial dysfunction and other adverse effects. The presence of cardiovascular risk factors and diseases has been shown to worsen the disease severity and increase mortality from COVID-19. Recent studies have also found that elevations in some serum cardiovascular biomarkers can stratify the disease severity, in particular rates of hospitalizations to an internal medicine or intensive care unit, intubation, and mortality. They can be divided into markers of damage (TnT/I, creatine phosphokinase (CPK) and CPK-MB, myoglobin, NT-proBNP), coagulation (prothrombin time, fibrinogen and D-dimer), as well as prospective biomarkers for which the available evidence base is limited but there is a pathophysiological rationale (homocysteine and sST2). This review presents studies on the use of above serum biomarkers to stratify the risk of death in patients with COVID-19.

Original language	English
Pages (from-to)	35-41
Number of pages	7
Journal	Russian Journal of Cardiology
Volume	26
Issue number	S2
DOIs	https://doi.org/10.15829/1560-4071-2021-4456
State	Published - 2021
Externally published	Yes

Keywords

Biomarkers
Cardiovascular events
COVID-19
Risk stratification
SARS-CoV-2

Access to Document

10.15829/1560-4071-2021-4456

Cite this

@article{a0ffe4c66cf5410fba65baca0928aae7,

title = "Serum biomarkers of cardiovascular complications in covid-19",

abstract = "The coronavirus disease 2019 (COVID-19) affects not only the respiratory system, but also the cardiovascular system in 20-28% of cases, causing endothelial dysfunction, vasculitis, hyper-and hypocoagulation, myocarditis, endothelial dysfunction and other adverse effects. The presence of cardiovascular risk factors and diseases has been shown to worsen the disease severity and increase mortality from COVID-19. Recent studies have also found that elevations in some serum cardiovascular biomarkers can stratify the disease severity, in particular rates of hospitalizations to an internal medicine or intensive care unit, intubation, and mortality. They can be divided into markers of damage (TnT/I, creatine phosphokinase (CPK) and CPK-MB, myoglobin, NT-proBNP), coagulation (prothrombin time, fibrinogen and D-dimer), as well as prospective biomarkers for which the available evidence base is limited but there is a pathophysiological rationale (homocysteine and sST2). This review presents studies on the use of above serum biomarkers to stratify the risk of death in patients with COVID-19.",

keywords = "Biomarkers, Cardiovascular events, COVID-19, Risk stratification, SARS-CoV-2",

author = "Gumerov, {R. M.} and Gareeva, {D. F.} and Davtyan, {P. A.} and Rakhimova, {R. F.} and Musin, {T. I.} and Zagidullin, {Sh Z.} and Pushkareva, {A. E.} and Plotnikova, {M. R.} and Ishmetov, {V. Sh} and Pavlov, {V. N.} and Motloch, {L. J.} and Zagidullin, {N. Sh}",

year = "2021",

doi = "10.15829/1560-4071-2021-4456",

language = "English",

volume = "26",

pages = "35--41",

journal = "Russian Journal of Cardiology",

issn = "1560-4071",

publisher = "Russian Society of Cardiology",

number = "S2",

}

TY - JOUR

T1 - Serum biomarkers of cardiovascular complications in covid-19

AU - Gumerov, R. M.

AU - Gareeva, D. F.

AU - Davtyan, P. A.

AU - Rakhimova, R. F.

AU - Musin, T. I.

AU - Zagidullin, Sh Z.

AU - Pushkareva, A. E.

AU - Plotnikova, M. R.

AU - Ishmetov, V. Sh

AU - Pavlov, V. N.

AU - Motloch, L. J.

AU - Zagidullin, N. Sh

PY - 2021

Y1 - 2021

N2 - The coronavirus disease 2019 (COVID-19) affects not only the respiratory system, but also the cardiovascular system in 20-28% of cases, causing endothelial dysfunction, vasculitis, hyper-and hypocoagulation, myocarditis, endothelial dysfunction and other adverse effects. The presence of cardiovascular risk factors and diseases has been shown to worsen the disease severity and increase mortality from COVID-19. Recent studies have also found that elevations in some serum cardiovascular biomarkers can stratify the disease severity, in particular rates of hospitalizations to an internal medicine or intensive care unit, intubation, and mortality. They can be divided into markers of damage (TnT/I, creatine phosphokinase (CPK) and CPK-MB, myoglobin, NT-proBNP), coagulation (prothrombin time, fibrinogen and D-dimer), as well as prospective biomarkers for which the available evidence base is limited but there is a pathophysiological rationale (homocysteine and sST2). This review presents studies on the use of above serum biomarkers to stratify the risk of death in patients with COVID-19.

AB - The coronavirus disease 2019 (COVID-19) affects not only the respiratory system, but also the cardiovascular system in 20-28% of cases, causing endothelial dysfunction, vasculitis, hyper-and hypocoagulation, myocarditis, endothelial dysfunction and other adverse effects. The presence of cardiovascular risk factors and diseases has been shown to worsen the disease severity and increase mortality from COVID-19. Recent studies have also found that elevations in some serum cardiovascular biomarkers can stratify the disease severity, in particular rates of hospitalizations to an internal medicine or intensive care unit, intubation, and mortality. They can be divided into markers of damage (TnT/I, creatine phosphokinase (CPK) and CPK-MB, myoglobin, NT-proBNP), coagulation (prothrombin time, fibrinogen and D-dimer), as well as prospective biomarkers for which the available evidence base is limited but there is a pathophysiological rationale (homocysteine and sST2). This review presents studies on the use of above serum biomarkers to stratify the risk of death in patients with COVID-19.

KW - Biomarkers

KW - Cardiovascular events

KW - COVID-19

KW - Risk stratification

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85117841902&partnerID=8YFLogxK

U2 - 10.15829/1560-4071-2021-4456

DO - 10.15829/1560-4071-2021-4456

M3 - Article

AN - SCOPUS:85117841902

SN - 1560-4071

VL - 26

SP - 35

EP - 41

JO - Russian Journal of Cardiology

JF - Russian Journal of Cardiology

IS - S2

ER -

Serum biomarkers of cardiovascular complications in covid-19

Abstract

Keywords

Access to Document

Fingerprint

Cite this